Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
556results about How to "Inhibit tumor growth" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Methods and Antibody Compositions for Tumor Treatment
ActiveUS20150266966A1Decreased killing of T-cellsReduce the burden onImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsDiseaseCD20
The present invention provides bispecific antibodies that bind to CD3 and tumor antigens and methods of using the same. According to certain embodiments, the bispecific antibodies of the invention exhibit reduced effector functions and have a unique binding profile with regard to Fcγ receptors. The bispecific antibodies are engineered to efficiently induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, a second antigen-binding molecule that specifically binds human CD20, and an Fc domain that binds Fcγ receptors with a specific binding pattern. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell or melanoma tumors expressing CD20. The bispecific antibodies of the invention are useful for the treatment of various cancers as well as other CD20-related diseases and disorders.
Owner:REGENERON PHARM INC
Phosphoinositide 3-kinase inhibitor compounds and methods of use
ActiveUS20080039459A1Inhibit tumor growthUseful in treatmentAntibacterial agentsOrganic active ingredientsMolecular biologyPharmaceutical medicine
Compounds of Formulas Ia and Ib, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
Owner:GENENTECH INC +1
Multi-arm polymer prodrugs
ActiveUS7744861B2Improve balanceHigh drug loadingPharmaceutical non-active ingredientsSynthetic polymeric active ingredientsWater soluble prodrugPolymer science
Provided herein are water-soluble prodrugs. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.
Owner:NEKTAR THERAPEUTICS INC
Multi-arm polymer prodrugs
ActiveUS20050112088A1Improve balanceHigh drug loadingPharmaceutical non-active ingredientsSynthetic polymeric active ingredientsWater soluble prodrugPolymer science
Provided herein are water-soluble prodrugs. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.
Owner:NEKTAR THERAPEUTICS INC
Human antibodies to PD-1
ActiveUS9987500B2Rescues T-cell signalingInhibit tumor growthNervous disorderAntipyreticFc(alpha) receptorDisease
The present invention provides antibodies that bind to the T-cell co-inhibitor programmed death-1 (PD-1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-1 and a second binding specificity that binds to an autoimmune tissue antigen, another T-cell co-inhibitor, an Fc receptor, or a T-cell receptor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-1 activity, thus providing a means of treating a disease or disorder such as cancer or a chronic viral infection. In other embodiments, the antibodies are useful for enhancing or stimulating PD-1 activity, thus providing a means of treating, for example, an autoimmune disease or disorder.
Owner:REGENERON PHARM INC
Triazole compounds that modulate Hsp90 activity
ActiveUS20060167070A1Reduced growth rateInhibit tumor growthBiocideOrganic chemistryTriazole antifungalsHSP90 Heat-Shock Proteins
The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.
Owner:SYNTA PHARMA CORP
Globo h and related Anti-cancer vaccines with novel glycolipid adjuvants
ActiveUS20100136042A1Shrink tumorInhibit tumor growthOrganic active ingredientsSugar derivativesDendritic cellAdjuvant
Owner:ACAD SINIC
Compositions and methods for tumor-targeted delivery of effector molecules
InactiveUS6962696B1Inhibit tumor growthReduce tumor volumeOrganic active ingredientsHeavy metal active ingredientsTumor targetMelanoma
The present application discloses the preparation and use of attenuated tumor-targeted bacteria vectors for the delivery of one or more primary effector molecule(s) to the site of a solid tumor. The primary effector molecule(s) of the invention is used in the methods of the invention to treat a solid tumor cancer such as a carcinoma, melanoma, lymphoma, or sarcoma. The invention relates to the surprising discovery that effector molecules, which may be toxic when administered systemically to a host, can be delivered locally to tumors by attenuated tumor-targeted bacteria with reduced toxicity to the host. The application also discloses to the delivery of one or more optional effector molecule(s) (termed secondary effector molecules) which may be delivered by the attenuated tumor-targeted bacteria in conjunction with the primary effector molecule(s).
Owner:NANOTHERAPEUTICS INC
Use of Pegylated IL-10 to Treat Cancer
InactiveUS20080081031A1Improved modulator of tumor growthReducing and inhibiting growth of tumorPeptide/protein ingredientsDigestive systemAbnormal tissue growthOncology
Owner:SCHERING CORP
Antibodies to interleukin-20 and method for inhibiting interleukin-20 induced cell proliferation
ActiveUS20060142550A1Stimulate tumor growthStimulate angiogenesisImmunoglobulins against cell receptors/antigens/surface-determinantsFermentationWhite blood cellProliferation activity
Antibody to human IL-20 protein, a method for generation thereof and cells producing this antibody are disclosed. The antibody of the present invention has specificity to neutralizing hIL-20W-induced CPAE proliferation activity, and is useful for treating IL-20-induced inflammation, such as artheriosclerosis and rheumatoid arthritis.
Owner:LBL BIOTECH INC
Compositions and Methods for Tumor-Targeted Delivery of Effector Molecules
InactiveUS20070298012A1Reduce Toxicity RiskReduce riskHeavy metal active ingredientsBiocideParanasal Sinus CarcinomaMelanoma
The present application discloses the preparation and use of attenuated tumor-targeted bacteria vectors for the delivery of one or more primary effector molecule(s) to the site of a solid tumor. The primary effector molecule(s) of the invention is used in the methods of the invention to treat a solid tumor cancer such as a carcinoma, melanoma, lymphoma, or sarcoma. The invention relates to the surprising discovery that effector molecules, which may be toxic when administered systemically to a host, can be delivered locally to tumors by attenuated tumor-targeted bacteria with reduced toxicity to the host. The application also discloses to the delivery of one or more optional effector molecule(s) (termed secondary effector molecules) which may be delivered by the attenuated tumor-targeted bacteria in conjunction with the primary effector molecule(s).
Owner:NANOTHERAPEUTICS INC
Cytotoxicity mediation of cells evidencing surface expression of TROP-2
InactiveUS20080131428A1Raise the possibilityEfficient targetingImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsDiseaseLymphatic Spread
Owner:ARIUS RES +1
Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds
InactiveUS6855723B2Reduce probabilityAlleviating and abrogating abnormal conditionBiocideOrganic chemistryBiological bodyThreonine
The present invention is directed in part towards methods of modulating the function of serine / threonine protein kinases with azabenzimidazole-based compounds. The methods incorporate cells that express a serine / threonine protein kinase, such as RAF. In addition, the invention describes methods of preventing and treating serine / threonine protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to azabenzimidazole compounds and pharmaceutical compositions comprising these compounds.
Owner:ZENTARIS GMBH
Compositions and methods for tumor-targeted delivery of effector molecules
InactiveUS20050249706A1Inhibit tumor growthReduce tumor volumeBiocideOrganic active ingredientsTumor targetAbnormal tissue growth
Owner:NANOTHERAPEUTICS INC
Method for increasing therapeutic gain in radiotherapy and chemotherapy
InactiveUS20050272644A1Inhibit tumor growthReduced radiation-induced normal tissue fibrosisBiocideAntipyreticAbnormal tissue growthTumor therapy
The present invention provides compositions and methods for increasing therapeutic gain in radiotherapy and chemotherapy for proliferating malignant or nonmalignant disease to produce high probability of tumor control with low frequency of sequelae of therapy by administering a therapeutically effective amount of a histone deacetylase inhibitor. The compounds are capable of simultaneously stimulating the epithelium regrowth, inhibiting the fibroblast proliferation, decreasing the collagen deposit, suppressing the fibrogenic growth factor, subsiding the proinflammatory cytokine and modulating the expression of cell cycle genes, tumor suppressors and oncogenes, and are useful to increase the therapeutic gain in radiotherapy and chemotherapy, which results in decrease of skin swelling and inflammation, promotion of epithelium healing in mucosa and dermis, decrease of xerostomia, prevention / reduction of severity of plantar-palmar syndrome, prevention of tissue fibrosis, ulceration, necrosis and tumorigenesis, and increase of tumor growth inhibition and tumor therapy effectiveness.
Owner:SUNNY PHARMTECH
Methods of treating cancer
ActiveUS20120070502A1High elongationLow toxicityPowder deliveryOrganic active ingredientsCarboplatinPlatinum
The present invention provides methods and compositions for treating non-small-cell lung cancer (NSCLC) by administering a) a composition comprising nanoparticles that comprise paclitaxel and an albumin and b) a platinum-based agent (e.g., carboplatin). The present application also provides methods of treating prostate cancer by administering to the individual a) an effective amount of a composition comprising nanoparticles comprising docetaxel and an albumin; and b) an effective amount of a steroid.
Owner:ABRAXIS BIOSCI LLC
Application of bacteroides fragilis in preparing composition for preventing and treating colon cancer
InactiveCN103142656AInhibit tumor growthPromote apoptosisMilk preparationBacteria material medical ingredientsBacillus fragilisTumor growth
The invention relates to the technical field of application of bacteroides fragilis, and in particular relates to application of bacteroides fragilis in preparing a composition for preventing and treating colon cancer. Experiments show that bacteroides fragilis induces an organism to generate the anti-tumor effect in vivo, inhibit the tumor growth, accelerate tumor cell apoptosis and prolong the lifetime, so that bacteroides fragilis has a good effect in preventing and treating colon cancer. The invention explores novel use of bacteroides fragilis and develops a novel application field, thereby indicating that the bacteroides fragilis has good edible and officinal prospect. Bacteroides fragilis serving as probiotic can be used for preparing foods or medical compositions for preventing and treating colon cancer so as to provide a clinically health-care and preventing and treating food suitable for human to take.
Owner:广州知光生物科技有限公司
Methods of treating cancer
ActiveUS20140072643A1Many symptomShorten the progressOrganic active ingredientsHeavy metal active ingredientsCarboplatinDocetaxel-PNP
The present invention provides methods and compositions for treating non-small-cell lung cancer (NSCLC) by administering a) a composition comprising nanoparticles that comprise paclitaxel and an albumin and b) a platinum-based agent (e.g., carboplatin). The present application also provides methods of treating prostate cancer by administering to the individual a) an effective amount of a composition comprising nanoparticles comprising docetaxel and an albumin; and b) an effective amount of a steroid.
Owner:ABRAXIS BIOSCI LLC
Combination immunotherapy compositions against cancer and methods
ActiveUS20120107347A1Reduces and prevents infectionInhibit tumor growthAntibacterial agentsAntimycoticsDiseaseCombination immunotherapy
Owner:GLOBE IMMUNE INC +1
Antibodies against csf-1r
ActiveUS20110243947A1Prevent dimerizationInhibit tumor growthImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsDocetaxel-PNPDocetaxel
The invention provides a human antibody that binds human CSF-1R with high affinity. Antibodies of the present invention have significant advantages over the antibodies known in the art by being multifunctional: inhibiting signaling of CSF-1R, internalizing and inducing CSF-1R degradation and stimulating ADCC in cell including tumors, macrophages and monocytes. They are also shown to be effective in treating leukemia, breast, endometrial and prostate cancer alone or in combination with docetaxel, paclitaxel, Herceptin® or doxorubicin.
Owner:IMCLONE SYSTEMS
Methods for immunotherapy of cancer
InactiveUS20060286074A1Reduce or eliminate impactAvoid immune responseBiocidePeptide/protein ingredientsAntigenTumor vessel
Provided are methods of generating an immune response to an antigen specifically associated with tumor vascular endothelial cells (TVECA). The method comprises administering to an individual an expression vector encoding the TVECA. The vector comprises a transcription unit encoding a secretable fusion protein, the fusion protein containing a TVECA and CD40 ligand. In other methods, administration of a fusion protein containing the TVECA and CD40 ligand is used to enhance the immune response above that obtained by vector administration alone. Further methods comprise the combination therapy using an expression vector encoding a secretable TVECA fusion protein and a tumor antigen vaccine.
Owner:SIDNEY KIMMEL CANCER CENT
Quinolyl-containing hydroxamic acid compound and preparation method thereof, and pharmaceutical composition containing this compound and use thereof
InactiveUS9186318B2Enhanced inhibitory effectInhibit tumor growthSenses disorderNervous disorderHydroxamic acidHistone deacetylase
Owner:BEIJING KONRUNS PHARM CO LTD
Attenuated salmonella as a delivery system for sirna-based tumor therapy
InactiveUS20090208534A1Promote growthConducive to survivalBacteriaSpecial deliveryTumor targetTumor targeting
The invention relates to an attenuated Salmonella sp. that is capable of targeting a solid tumor when administered in vivo comprising a short hairpin (sh) RNA construct, and methods of inhibiting the growth or reducing the volume of a solid tumor cancer comprising administering an effective amount of an attenuated Salmonella sp. to a patient having a solid tumor cancer, wherein said attenuated Salmonella sp. is a tumor targeting attenuated Salmonella sp. expressing a short hairpin (sh) RNA which attenuated Salmonella sp. is capable of inhibiting the growth or reducing the volume of the solid tumor cancer when administered in vivo.
Owner:JILIN UNIV +2
Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
ActiveUS20100316640A1Inhibit tumor growthReduce the total massHeavy metal active ingredientsBiocideAnticoagulant activityPolysaccharide
Polysaccharide preparations lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided.
Owner:DILAFOR
Methods for treating brain tumors
InactiveUS20120157402A1Limiting solid tumor growthLimiting tumor-related inflammationBiocideCarbohydrate active ingredientsBrain tumorCancer research
Methods for treating brain tumors involving the administration of a compound that selectively inhibits pathological production of human VEGF are described. The compound can be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatment.
Owner:PTC THERAPEUTICS INC
Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
InactiveUS20100233164A1Growth inhibitionInhibit tumor growthBiocideMicrobiological testing/measurementKinase inhibitionHematopoietic malignancy
Combinations of PI3K inhibitor compounds having Formula I and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hematopoietic malignancies. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
Owner:GENENTECH INC
Inhibition of STAT3 signal transduction for human cancer therapy
InactiveUS20070060521A1Improve efficiencyIncrease in intracellular expression of Bcl-xOrganic active ingredientsFungiAbnormal tissue growthHuman cancer
Signal Transducer and Activator of Transcription (STAT) proteins have a fundamental role cell signaling, and are activated by a large number of cytokines and growth factors. One member of the STAT family, STAT3, has a critical role in oncogenesis. The present invention relates generally to disruption of the pathway of STAT3 signaling in the treatment of human cancer. STAT3 activation is shown to be present in diverse tumor cell lines and tumors, to promote oncogenesis, to inhibit apoptosis, and to reduce sensitivity to chemotherapeutic agents. Inhibition of STAT3 signaling induces apoptosis specifically in tumor cell lines, and increases sensitivity to chemotherapeutic agents. The invention relates more particularly to methods, compositions, means of administering such compositions, and means for identifying such compositions for the inhibition of STAT3 intracellular signaling in the treatment of human cancers.
Owner:YALE UNIV +1
Methods and composition for restoring conformational stability of a protein of the p53 family
InactiveUS20020048271A1Wide applicabilityInhibit tumor growthBiocideSenses disorderMutated proteinWild type
The invention is in the field of cancer treatment. In particular, the present invention provides pharmaceutical compounds capable of interacting with mutant and non-mutant forms of cancer-related regulatory proteins such that the mutant protein regains the capacitv to properly interact with other macromolecules thereby restoring or stabilizing all or a portion of its wild type activity. Regulatory proteins include members of the p53 protein family such as. for example, p53, p63 and p73. The compounds of the invention are useful for cancer treatment. Methods for screening for such pharmacological compounds are also provided.
Owner:RASTINEJAD FARZAN +3
Pharmaceutical Compositions Comprising RET Inhibitors and Methods for the Treatment of Cancer
InactiveUS20110201598A1Inhibit tumor growthReduce transferBiocideOrganic compound preparationCancer preventionPancreas Cancers
A class of compounds useful in pharmaceutical compositions and methods for treating or preventing cancer is described. The compounds' ability to inhibit RET kinase is quantified, i.e., their respective RET IC50 and EC50 values are described. One such compound, known as cyclobenzaprine and herein as SW-01, has been identified as RET-specific with an IC50 of 300 nM. SW-01 inhibits RET autophosphorylation and blocks the growth and transformation of thyroid cancer cell lines. It has been further tested in pancreatic cancer, breast cancer, and SCLC cell lines. The compounds show utility for inhibition of survival and proliferation of tumour cells.
Owner:SINGH VINAY K +2
Cytotoxicity mediation of cells evidencing surface expression of TROP-2
InactiveUS20080213267A1Reduce the likelihood of problemsReduce the overall heightOrganic active ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsLymphatic SpreadCytokine
This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB / chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays, which utilize the CDMAB of the instant invention. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.
Owner:F HOFFMANN LA ROCHE INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com